NCT00051909已完成2 期
Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 9
研究概览
简要总结
Study of an investigational medication for the treatment of Alzheimer's Disease in patients who are not taking Aricept, Reminyl, Exelon.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Must have a clinical diagnosis of Alzheimer's Disease
- •Must be at least 50 years of age
- •Must fluently read and speak English
- •Must have a reliable caregiver
排除标准
- •Has serious health problems other than Alzheimer's Disease
- •Cannot swallow whole pills
- •Has had a menstrual period in the last two years
- •Takes insulin for diabetes
- •Has taken Aricept, Reminyl, or Exelon in the last 5 weeks
研究者
研究点 (9)
Loading locations...
相似试验
已完成
1 期
A Biomarker-directed Study of XPro1595 in Patients With Alzheimer'sAlzheimer DiseaseNCT03943264Inmune Bio, Inc.20
终止
2 期
A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease DementiaAlzheimer's DiseaseNCT02791191Eli Lilly and Company316
已完成
1 期
Bisnorcymserine in Healthy Adult VolunteersHealthy VolunteersNCT01747213National Institute on Aging (NIA)75
已完成
3 期
Safety of SPD465 in Treating Adults With ADHD.Attention Deficit Disorder With HyperactivityNCT00152035Shire505
已完成
2 期
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's PatientsAlzheimer DiseaseNCT00141661Pfizer67